What is Phathom Pharmaceuticals?
Phathom Pharmaceuticals is a biopharmaceutical firm operating in the late clinical-stage, dedicated to the advancement and commercialization of innovative therapies for gastrointestinal (GI) disorders. The company's lead candidate is vonoprazan, an investigational potassium-competitive acid blocker (P-CAB) currently in late-stage clinical development. This compound holds the potential to be the first new class of gastric anti-secretory agent approved in the United States, Europe, or Canada in over three decades, marking a significant therapeutic innovation.
How much funding has Phathom Pharmaceuticals raised?
Phathom Pharmaceuticals has raised a total of $260M across 1 funding round:
Debt
$260M
Debt (2022): $260M with participation from Sagard Healthcare Partners, Hercules Capital, and NovaQuest Capital Management
Key Investors in Phathom Pharmaceuticals
Sagard Healthcare Partners
Sagard Healthcare Partners is an investment firm focused on the healthcare sector, likely providing strategic capital to companies advancing therapeutic innovations.
Hercules Capital
Hercules Capital is a specialty finance company that provides debt financing solutions to technology and life science companies, supporting their growth and development.
NovaQuest Capital Management
NovaQuest Capital Management is a premier biopharma and life sciences investment firm that pioneered a product finance investment solution, providing at-risk, nondilutive funding to advance pivotal clinical trials and launch new brands.
What's next for Phathom Pharmaceuticals?
The substantial enterprise-level funding, particularly the recent strategic investment, signals Phathom Pharmaceuticals' readiness to advance vonoprazan through its final clinical trials and prepare for potential regulatory submissions and market launch. This capital infusion is critical for scaling operations, expanding the clinical development team, and navigating the complex regulatory pathways required for bringing a novel therapeutic to market. The company's focus on a significant unmet need in GI disorders, coupled with a potentially first-in-class asset, positions it for substantial growth and value creation.
See full Phathom Pharmaceuticals company page
